U.S. markets closed
S&P Futures
3,341.00-3.75(-0.11%)Dow Futures
27,305.00-28.00(-0.10%)Nasdaq Futures
11,101.50-21.25(-0.19%)
Xenetic Biosciences, Inc. (XBIO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2500-0.0500 (-3.85%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 1.3000 |
| Open | 1.3000 |
| Bid | 1.2400 x 1200 |
| Ask | 1.2600 x 2200 |
| Day's Range | 1.2100 - 1.3000 |
| 52 Week Range | 0.4400 - 2.2100 |
| Volume | 189,352 |
| Avg. Volume | 634,415 |
| Market Cap | 7.856M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.3340 |
| Earnings Date | May 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.25 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- ACCESSWIRE
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
* Jia Xie, PhD, a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy * Alexey V.
- ACCESSWIRE
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
XCART technology platform is a significantly differentiated, proprietary approach to personalized CAR T therapy for the treatment of multiple tumor types of B-cell Non-Hodgkin lymphoma (NHL) Recently secured ...
- ACCESSWIRE
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform
Goal of XCART collaboration to optimize XCART process, develop manufacturing processes and to ultimately dose non-Hodgkin lymphoma (NHL) patients Pharmsynthez to act as primary contract research organization ...
© 2020 Verizon Media. All rights reserved.
